Nerve Blocks for the Treatment of COVID-19 Headache: Aarushi Suneja, MD
The headache fellow at Cleveland Clinic outlined the design and reasoning for a new study assessing nerve blocks to treat COVID-19 headache.
"The aim of this study is both descriptive and interventional in that sense. We plan to evaluate the effectiveness of COVID-19-related headaches within reflux, but also in comparison to conventional pharmacologic treatments for excess migraineosis, or severe tension type headache.”
According to the Centers for Disease Control (CDC), 50% of patients diagnosed with SARS-CoV-2 will present with a headache as an initial symptom which often persists in the post infectious period. At the
Bilateral occipital nerve blocks with pharmacological treatments such as steroids, Parafon Forte burst, Depakote burse, dihydroergotamine, and infusion therapy—all considered standard of care approaches—will be evaluated for their effectiveness at 1- and 2-month intervals. Led by Aarusha Suneja, MD, the hope is to develop a new standard of care for this novel headache type that has become increasingly prevalent.
Suneja, a headache fellow at
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.